Skip to main content

Advertisement

Table 3 Frequency of mild-to-moderate adverse events on days 1–7 (related or not to treatment) with three artemisinin-containing combinations therapies in comparison with amodiaquine + sulphadoxine–pyrimathamine (AQ-SP)

From: Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial

  AS-SMP AS-AQ AL AQ-SP p
N = 58 N = 68 N = 60 N = 65
At least one adverse event 24 35 17 32 0.037
% (95% CI) 41% (29–55) 51% (39–64) 28% (17–41) 49% (37–62)  
Vomiting 10 12 4 12 0.177
Fever 11 14 8 6 0.143
Fatigue 4 9 3 16 0.006
Abdominal pain 3 8 2 9 0.112
Diarrhoea 4 6 4 5 0.976
Anorexia 3 4 3 8 0.377
Pruritus 2 4 0 4 0.222
Drowsiness 0 0 0 2 0.175
Aphthous stomatitis 0 1 0 1 1.000
Headache 1 0 1 0 0.359
Other* 6 7 3 6 0.666
  1. AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine (Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number; CI, Confidence interval. In bold: the only adverse event for which statistically significant differences (p <0.01) are observed between the treatments.
  2. *Intestinal, respiratory, skin infections, pain, anaemia, cough, injuries, skin rash.